|13.77||+0.0200||+0.15%||Vol 1.19M||1Y Perf 64.67%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||-0.02 -0.15%|
|Target Price||12.35||Analyst Rating||Strong Buy 1.11|
|Potential %||-10.31||Finscreener Ranking||☆ 31.57|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||☆ 33.52|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||☆ 19.02|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||71.82||Earnings Rating||Strong Sell|
|Market Cap||1.24B||Earnings Date||8th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.35|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||710.53K|
|Avg. Monthly Volume||770.87K|
|Avg. Quarterly Volume||587.71K|
Avadel Pharmaceuticals plc (NASDAQ: AVDL) stock closed at 13.77 per share at the end of the most recent trading day (a 0.15% change compared to the prior day closing price) with a volume of 1.19M shares and market capitalization of 1.24B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 50 people. Avadel Pharmaceuticals plc CEO is Gregory J. Divis.
The one-year performance of Avadel Pharmaceuticals plc stock is 64.67%, while year-to-date (YTD) performance is 92.32%. AVDL stock has a five-year performance of 415.73%. Its 52-week range is between 5.92 and 16.85, which gives AVDL stock a 52-week price range ratio of 71.82%
Avadel Pharmaceuticals plc currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 7.63, a price-to-sale (PS) ratio of 42.02, a price to cashflow ratio of 16.60, a PEG ratio of -, a ROA of -71.62%, a ROC of -67.44% and a ROE of -370.73%. The company’s profit margin is -46.60%, its EBITDA margin is 24.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Avadel Pharmaceuticals plc, there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.35 for the next earnings report. Avadel Pharmaceuticals plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Avadel Pharmaceuticals plc is Strong Buy (1.11), with a target price of $12.35, which is -10.31% compared to the current price. The earnings rating for Avadel Pharmaceuticals plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avadel Pharmaceuticals plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avadel Pharmaceuticals plc has a Buy technical analysis rating based on Technical Indicators (ADX : 14.56, ATR14 : 0.77, CCI20 : 251.96, Chaikin Money Flow : -0.01, MACD : 0.54, Money Flow Index : 77.07, ROC : 28.26, RSI : 72.49, STOCH (14,3) : 94.92, STOCH RSI : 1.00, UO : 66.24, Williams %R : -5.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avadel Pharmaceuticals plc in the last 12-months were: Divis Greg (Buy at a value of $132 000), Ende Eric (Buy at a value of $181 090), Linda Palczuk (Buy at a value of $36 900)
Wed, 04 Oct 2023 11:50 GMT Avadel Pharmaceuticals added to Conviction List at Needham- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.